Does THC Inhibit CYP1B1?
Yes, THC inhibits CYP1B1 activity, though it is a less potent inhibitor compared to other major cannabinoids like cannabidiol (CBD) and cannabinol (CBN).
Evidence for CYP1B1 Inhibition
The most definitive evidence comes from in vitro studies demonstrating that THC competitively inhibits CYP1B1 enzyme activity. THC inhibits CYP1B1 with an apparent Ki value of 2.47-7.54 μM, which is substantially higher (indicating weaker inhibition) than the Ki values observed for CBD (0.155 μM for CYP1A1) and CBN (0.148 μM for CYP1B1) 1. This means THC requires higher concentrations to achieve the same degree of enzyme inhibition compared to the other major phytocannabinoids.
Multiple research studies consistently confirm that all three major cannabinoids—THC, CBD, and CBN—inhibit CYP1B1, CYP1A1, and CYP1A2 enzymes 2, 3. The inhibition is direct and competitive in nature, meaning THC competes with other substrates for the enzyme's active site.
Clinical Context and Relevance
While the ASCO guidelines acknowledge that cannabis and cannabinoids inhibit multiple cytochrome P450 family enzymes (specifically listing CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2C19), they notably do not specifically mention CYP1B1 in their clinical guidance 4. This omission likely reflects that:
- CYP1B1 plays a more limited role in drug metabolism compared to the major hepatic CYP enzymes
- The clinical significance of CYP1B1 inhibition is less well-established for common medications
- Most clinically relevant drug-drug interactions involve the hepatic CYP enzymes rather than extrahepatic enzymes like CYP1B1
Important Caveats
The inhibition of CYP1B1 by THC occurs at concentrations that may or may not be clinically achievable depending on the route of administration and dosing. The research demonstrates inhibition in vitro, but translating these findings to clinical practice requires consideration of:
- Bioavailability varies dramatically by route: oral THC has only 4-12% bioavailability versus 10-35% for inhaled THC 4
- Tissue distribution: THC is highly lipid-soluble and accumulates in adipose tissue, which can lead to gradual release over time 4
- Concentration at the enzyme site: systemic THC concentrations may differ from local tissue concentrations where CYP1B1 is expressed
Practical Implications
For clinical decision-making, the key takeaway is that THC does inhibit CYP1B1, but this is unlikely to be the primary concern for drug-drug interactions in most patients. The more clinically relevant interactions involve:
- CYP2C9 and CYP2C19: where warfarin interactions are classified as very high risk 4
- CYP3A4: which metabolizes many chemotherapeutics and common medications 4
- CYP1A2: which shows induction (not just inhibition) with cannabis smoking 2
When counseling patients using THC-containing products, focus on monitoring for interactions with drugs metabolized by the major hepatic CYP enzymes rather than specifically worrying about CYP1B1 substrates, unless the patient is taking a medication known to be primarily metabolized by this enzyme.